The parkinsonism-hyperpyrexia syndrome.

Neurocritical Care
Edward J NewmanPeter G E Kennedy

Abstract

The parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal complication seen in Parkinson's disease (PD) patients, most commonly following reduction or cessation of antiparkinson medications. Clinically it resembles neuroleptic malignant syndrome with rigidity, pyrexia, and reduced conscious level. There may be features of autonomic instability, and serum creatine kinase (CK) may be elevated. Complications of PHS include acute renal failure, aspiration pneumonia, deep venous thrombosis/pulmonary embolism, and disseminated intravascular coagulation (DIC). Management consists of dopaminergic drug replacement, supportive measures, and treatment of complications. The prognosis is improved with early recognition and management. Mortality of up to 4% has been reported, but an additional one-third of patients have permanent sequelae. Patients and physicians should be warned against sudden reduction in antiparkinson medications. PHS should always be considered in a patient with parkinsonism who presents with an acute deterioration in symptoms.

References

Jun 1, 1991·The American Journal of Psychiatry·H Sternbach
Oct 1, 1989·Archives of General Psychiatry·P E KeckA A Nierenberg
Sep 19, 1985·The New England Journal of Medicine·R MayeuxL Cote
May 1, 1981·The Journal of Nervous and Mental Disease·M ToruK Sugano
Jul 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·M KonagayaY Konagaya
Dec 18, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·P H Gordon, S J Frucht
Apr 18, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·Y SatoK Satoh
May 9, 2003·Parkinsonism & Related Disorders·Takao HashimotoNobuo Yanagisawa
May 9, 2003·Parkinsonism & Related Disorders·Hideki TakuboHirotaro Narabayashi
Sep 25, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine GrossetDonald Grosset
Dec 8, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher M KippsJohn G L Morris
Jan 28, 2006·International Journal of Geriatric Psychiatry·J B Grace, P Thompson
Apr 19, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J ShimadaT Hattori
Nov 3, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Stewart A Factor
Jan 24, 2007·Parkinsonism & Related Disorders·K Nadia MagdalinouBelinda Kessel
Apr 26, 2007·Orphanet Journal of Rare Diseases·Henry RosenbergKathryn Stowell

❮ Previous
Next ❯

Citations

Mar 17, 2011·Clinical Medicine : Journal of the Royal College of Physicians of London·Sion L Jones, John V Hindle
Dec 18, 2013·The American Journal of Medicine·Linn Katus, Alexander Shtilbans
Mar 8, 2013·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Eiichirou UrasakiYuzo Yamakawa
Apr 8, 2011·Neurología : publicación oficial de la Sociedad Española de Neurología·A MariscalUNKNOWN Sociedad Española de Neurología
Mar 15, 2011·Cirugía española·Ana MariscalJuan Carlos Martínez Castrillo
Nov 16, 2010·The Journal of Emergency Medicine·Zoe D HowardDavid F M Brown
Mar 20, 2015·Rinshō shinkeigaku = Clinical neurology·Soutarou TaguchiManabu Doyu
Mar 13, 2016·Neurología : publicación oficial de la Sociedad Española de Neurología·J L Camacho VelásquezJ A Mauri Llerda
Nov 5, 2015·Journal of Neurology·Carlo Alberto ArtusiLeonardo Lopiano
Sep 5, 2015·Geriatrics & Gerontology International·Arjun PoudelIan A Scott
Aug 25, 2015·Parkinsonism & Related Disorders·Shyla T GovindappaUday B Muthane
Oct 2, 2012·Parkinsonism & Related Disorders·David James DaleyKatherine Helen O'Leary Deane
Dec 17, 2014·CNS Drugs·Naveed Malek, Donald G Grosset
Jul 30, 2016·Current Treatment Options in Neurology·Linn E Katus, Steven J Frucht
Oct 2, 2009·Journal of the Neurological Sciences·Donald Grosset, UNKNOWN European PD Therapy Compliance Study Group
Dec 7, 2010·Neurología : publicación oficial de la Sociedad Española de Neurología·A Mínguez-Castellanos
Nov 8, 2013·The Neurohospitalist·John ProbascoMichael Levy
Jun 24, 2017·Health Services Insights·Manjeet Singh DhalluSridhar Chilimuri
Dec 12, 2013·British Journal of Hospital Medicine·Alok Arora, Peter Fletcher
Jan 1, 2013·The Journal of Nervous and Mental Disease·Federica LuchiniFrancesco Casamassima
Dec 14, 2017·Neurologia i neurochirurgia polska·Mehmet Osman AkçakayaTalat Kırış
Jun 4, 2010·Critical Care Medicine·Karen J McAllen, David R Schwartz
Feb 23, 2020·Critical Care Nursing Quarterly·Jeffrey Mucksavage, Keri S Kim
Mar 4, 2020·Acta neurologica Belgica·Ho-Sung Ryu, Seok-Yeol Yang
Apr 18, 2020·Practical Neurology·Sacha E GandhiVicky L Marshall
May 17, 2019·BMJ Case Reports·Jehad AzarMona Soliman
Dec 21, 2018·BMJ Case Reports·Harsh SahuNaval Kishore Vikram
Feb 16, 2017·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Stanley N Caroff
Sep 23, 2020·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Abhishek LenkaFernando Luis Pagan
Dec 29, 2020·Journal of Parkinson's Disease·Michael F SalvatoreVicki A Nejtek
Apr 20, 2021·Expert Opinion on Drug Safety·Minghua TaoXin Tian

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.